US Corporate Distress Financial Stress SEC Filings — June 08, 2026

08-06-2026

Bluejay Diagnostics announced a private placement of up to $23.6 million, with $8.5 million upfront and up to $15.1 million from warrant exercises. The offering is priced at $2.325 per share and includes series G and H warrants. Net proceeds are expected to extend cash runway into Q1 2027, beyond FDA submission, and potentially beyond FDA approval if warrants are exercised. However, there is no assurance that warrants will be exercised, and the company faces risks related to FDA approval and commercialization.

• · Purchase price per share (or pre-funded warrant) and accompanying warrants: $2.325
• · Series G warrant exercise price: $2.075 per share, expires 5 years from effective date of resale registration statement
• · Short-term series H warrant exercise price: $2.075 per share, expires 24 months from effective date
• · Offering expected to close on or about June 3, 2026
• · Net proceeds intended for FDA approval activities, clinical studies, R&D, and working capital
• · Securities are unregistered and offered under Section 4(a)(2) and Regulation D

08-06-2026

SUNation Energy, Inc. (SUNE) and Suniva have signed a definitive reverse merger agreement, under which Suniva will merge with a SUNation subsidiary and the combined company will operate under the Suniva name on Nasdaq. Pre-merger SUNation stockholders are expected to own approximately 1.8% of the combined company with an implied value of ~$2.26 per share (a ~100% premium over SUNE's last closing price), while Suniva stockholders will own ~98.2%. The transaction is targeted to close in the second half of 2026, subject to stockholder approvals, SEC effectiveness of a Form S-4, and Nasdaq listing clearance.

• · Suniva is the largest and oldest U.S. merchant manufacturer of high-efficiency monocrystalline silicon solar cells.
• · Suniva's existing 1 GW nameplate cell facility operates in Georgia; expansion of 4.5 GW in Laurens County, South Carolina is supported by expected financing targeted to close later this month (June 2026).
• · The U.S. has roughly 59 GW of solar module-assembly capacity but only about 3 GW of operational cell capacity.
• · Suniva intends to become the leading domestic solar cell supplier serving a more than 500 GW market over the next decade.
• · SUNation's largest markets include New York, Florida and Hawaii; 2025 gross margins improved into the high-30-percent range.
• · The combined company's board is expected to consist of five members, all designated by Suniva.
• · Certain key SUNation stockholders holding ~10.4% entered into voting agreements in support of the transaction.
• · The transaction is subject to risks including the One Big Beautiful Act of 2025, which has had a material negative impact on residential solar installations since January 2026.

08-06-2026

GoHealth, Inc. has initiated a voluntary prepackaged Chapter 11 bankruptcy process to restructure its balance sheet, supported by 100% of its lenders, over 60% of Class A common stockholders, and over 99% of GoHealth Holdings, LLC interest holders. The company expects to continue operations without interruption and emerge before the 2026 annual enrollment period, with ownership transitioning to certain lenders. However, the restructuring will result in the delisting of Class A common stock from Nasdaq, and existing common equity holders will receive only limited recovery, reflecting a significant loss of value for shareholders.

• · The restructuring will reinstate preferred equity of GoHealth, Inc. and provide payment in full for trade payables and other ordinary course obligations.
• · A cash payment will be provided to holders of GoHealth common equity, though the amount is not specified.
• · The company expects Class A common stock to be delisted from Nasdaq and subsequently quoted on the OTCQB Basic Market or another over-the-counter market.
• · GoHealth has filed customary motions with the Bankruptcy Court to maintain uninterrupted operations and pay vendors and suppliers in full.
• · The restructuring is expected to be completed before the start of the 2026 annual enrollment period (AEP).

08-06-2026

Alpha Modus Holdings, Inc. filed an 8-K on June 8, 2026, announcing a 1-for-40 reverse stock split of its common stock, effective June 15, 2026, subject to Nasdaq approval. The reverse split does not change the authorized share count and fractional shares will be rounded up. The amendment was adopted by the board and stockholders.

• · Reverse stock split ratio is 1-for-40.
• · Effective time is the later of 7:00 a.m. New York Time on June 15, 2026, or Nasdaq approval and processing.
• · No fractional shares will be issued; all fractional shares will be rounded up to the nearest whole share.
• · Authorized share count remains unchanged.
• · Certificate of Amendment was signed on June 3, 2026.

08-06-2026

Ares Capital Corporation (ARCC) announced the establishment of its inaugural $1 billion commercial paper program, allowing issuance of short-term unsecured notes to reduce funding costs. The program is backstopped by the company's $5.5 billion Revolving Credit Facility, and proceeds will be used for general corporate purposes. No negative or flat metrics are present in this filing.

• · The commercial paper notes are unsecured and rank pari passu with the company's other senior unsecured indebtedness.
• · The notes will not be registered under the Securities Act of 1933 and are offered only through definitive offering documentation.
• · Ares Capital was the largest publicly traded BDC by market capitalization as of March 31, 2026.
• · The company was founded in 2004 and is externally managed by a subsidiary of Ares Management Corporation.

08-06-2026

Strive, Inc. (ASST) filed an 8-K on June 5, 2026, announcing amendments to its Series A Perpetual Preferred Stock (SATA) certificate of designation to increase authorized shares to 40,000,000, and entered into amended and restated sales agreements with multiple agents to sell up to $2.55 billion of Common Stock and up to $2.6 billion of SATA Stock through at-the-market offerings. The company also added several new sales agents, including Barclays Capital Inc., Clear Street LLC, The Benchmark Company, LLC, StoneX Financial Inc., B. Riley Securities, Inc., Maxim Group LLC, and H.C. Wainwright & Co., LLC. No financial results or period-over-period comparisons are provided in this filing.

• · The Certificate of Amendment for SATA Stock was filed with the Nevada Secretary of State on June 5, 2026, and is effective June 5, 2026, for the first amendment and June 15, 2026, at 12:01 am PT for the second amendment.
• · The A&R ASST Sales Agreement adds Barclays Capital Inc., Clear Street LLC, The Benchmark Company, LLC, StoneX Financial Inc., B. Riley Securities, Inc., Maxim Group LLC, and H.C. Wainwright & Co., LLC as additional agents alongside Cantor Fitzgerald & Co.
• · The A&R SATA Sales Agreement adds The Benchmark Company, LLC, StoneX Financial Inc., B. Riley Securities, Inc., Maxim Group LLC, and H.C. Wainwright & Co., LLC as additional agents alongside the original agents (Cantor Fitzgerald & Co., Barclays Capital Inc., Clear Street LLC).
• · The legal opinions of Brownstein Hyatt Farber Schreck, LLP regarding the validity of the shares are filed as Exhibits 5.1 and 5.2.

08-06-2026

MSD Investment Corp. amended its Senior Secured Credit Agreement to increase the limit on Shorter Term Unsecured Indebtedness from $200,000,000 to $600,000,000, tripling the allowable amount. The amendment, effective June 5, 2026, was executed with JPMorgan Chase as administrative agent and a syndicate of lenders including Goldman Sachs, Deutsche Bank, Morgan Stanley, and others. The filing does not disclose any negative or flat performance metrics, but the increased debt capacity may signal higher leverage or growth financing needs.

• · The amendment also corrected a reference from 'HSBC Bank USA' to 'HSBC Bank USA, N.A.' in the existing credit agreement.
• · The amendment was governed by New York law and included a jury trial waiver.
• · No Default or Event of Default existed immediately prior to or after the amendment effective date, as represented by the borrower.

08-06-2026

AVITA Medical, Inc. issued a warrant to Perceptive Credit Holdings V, LP on June 5, 2026, following stockholder approval at the 2026 Annual Meeting on June 3, 2026. The warrant allows Perceptive to purchase up to 500,000 shares of common stock at $3.4019 per share, with an additional 150,000 shares vesting if the Company draws the $10 million Additional Commitment Amount under the existing $60 million credit facility. The warrant shares are registered under the Company's existing S-3 registration statement.

• · The warrant exercise price is $3.4019 per share.
• · The warrant shares are registered under Registration Statement on Form S-3 (File No. 333-294790) with a prospectus supplement filed on June 5, 2026.
• · The Additional Commitment Amount of $10 million is subject to a net revenue requirement and must be drawn by March 31, 2027.
• · The Credit Agreement was originally entered into on January 13, 2026.

08-06-2026

Silver Star Properties REIT, Inc. filed for Chapter 11 bankruptcy on May 28, 2026, along with its subsidiary Silver Star Virginia Parkway, LLC. The company is the guarantor of four loan agreements currently in default, with outstanding principal amounts of $24,599,690, $15,530,000, $17,000,000, and $8,100,000. Additionally, a promissory note of $5,750,000 is in default and the related property has been posted for foreclosure.

• · The Chapter 11 cases are filed in the United States Bankruptcy Court for the Northern District of Texas under case numbers 26-42316-mxm11 (Silver Star) and 26-42315-mxm11 (McKinney Debtor).
• · The McKinney Debtor's promissory note matures on June 7, 2026, and the lender has posted the storage property for foreclosure on June 2, 2026.
• · The company issued a press release on June 5, 2026, announcing the bankruptcy filing and its strategic path forward.

08-06-2026

Volato Group announced a $2.2 million strategic investment led by Catheter Precision and other institutional investors, strengthening its balance sheet as it pivots to an AI-focused strategy. The company is evaluating two non-binding LOIs for AI infrastructure and power generation transactions, but no definitive agreements exist and the M2i Global transaction was recently terminated. While the investment provides near-term liquidity, the AI strategy remains highly speculative with no guaranteed outcomes.

• · The investment is in restricted common stock and subject to customary closing conditions, including NYSE American authorization of a supplemental listing application.
• · Volato owns Parslee, an AI software platform focused on deterministic document intelligence, and is developing Volato AI for aviation-specific AI agents.
• · The M2i Global transaction was recently terminated, but Volato believes this does not affect its NYSE American compliance plan.
• · No definitive agreements have been executed for the AI infrastructure opportunities, and there is no assurance either will result in a completed transaction.
• · Catheter Precision becomes Volato's largest shareholder as a result of this investment.

08-06-2026

Catheter Precision, Inc. (VTAK) entered into a Securities Purchase Agreement on June 7, 2026, to purchase 2,941,176 shares of Volato Group, Inc. (SOAR) at $0.34 per share for an aggregate purchase price of $1,000,000 in a private placement. As of June 5, 2026, the market value of these shares was approximately $1,000,000, and Volato also agreed to deliver freely tradeable equity securities of a third-party entity valued at approximately $1,100,000. However, the company cautioned there is no guarantee it will realize these current values through future sales.

• · The closing of the private placement is subject to customary conditions including accuracy of representations and warranties, performance of covenants, and absence of a Material Adverse Effect with respect to Volato.
• · Volato agreed to file a registration statement on Form S-3 covering resale of the shares within 10 calendar days of the Registration Rights Agreement and use best efforts to have it declared effective promptly.
• · The Registration Rights Agreement includes customary provisions for registration procedures, expenses, liquidated damages, and indemnification.

08-06-2026

Clean Energy Technologies, Inc. (CETY) entered into a subordinated business loan and security agreement on May 27, 2026, with Agile Capital Funding, LLC and Agile Lending, LLC for a term loan. The loan proceeds will be used to pay off an existing balance of $24,546.64 and fund general business requirements. The agreement includes a make-whole premium on prepayments and a default interest rate increase of 5.00%.

• · The loan is subordinated and secured by a security interest in the borrower's collateral.
• · Borrower must pay a make-whole premium equal to all interest that would have been paid through the Maturity Date upon any prepayment.
• · Interest is computed on a 360-day year basis.
• · The loan may not be reborrowed once repaid.
• · Borrower represents that there is no pending litigation involving more than $500,000.

08-06-2026

Nurix Therapeutics announced a global collaboration with Roche to co-develop and co-commercialize bexobrutideg, a potential best-in-class BTK degrader, across malignant hematology, immunology, and neurology. Nurix will receive an upfront cash payment of $700 million and is eligible for up to $2.3 billion in milestones, with profits and losses shared equally in the U.S. and royalties on ex-U.S. sales. The collaboration includes a robust clinical development plan, but Nurix faces risks from sharing 40% of development costs and the need to establish a U.S. commercialization infrastructure.

• · Development costs shared 40% Nurix, 60% Roche.
• · U.S. profits and losses split equally.
• · Nurix eligible for low- to high-teens royalties on ex-U.S. sales.
• · Bexobrutideg is an oral, brain-penetrant BTK degrader targeting wild-type and mutant BTK.
• · Phase 2 trials planned in multiple sclerosis (MS) and chronic spontaneous urticaria (CSU).
• · Goldman Sachs acted as exclusive financial advisor to Nurix.

08-06-2026

aTyr Pharma received a Nasdaq deficiency notice on December 4, 2025, for failing to maintain a minimum bid price of $1.00 per share for 30 consecutive business days. The company was granted an additional 180-day compliance period until November 30, 2026, to regain compliance, but there is no assurance of success and delisting remains a risk if the bid price does not meet the requirement.

• · The initial deficiency notice was received on December 4, 2025.
• · The initial compliance deadline was June 2, 2026, which the company failed to meet.
• · The company is eligible for the second compliance period because it meets all other continued listing standards except the minimum bid price.
• · If compliance is not achieved by November 30, 2026, Nasdaq will issue a delisting notice, which the company may appeal.
• · The company intends to monitor the bid price and may consider a reverse stock split to cure the deficiency.

08-06-2026

IGC Pharma, Inc. filed an 8-K on June 8, 2026, reporting the entry into a material agreement (Exhibit 10.1) under Items 1.01 and 2.03. The filing does not disclose specific financial terms or performance metrics, making it a procedural disclosure of a contractual obligation.

• · Filing type is 8-K (current report) dated June 8, 2026.
• · Items reported: 1.01 (Entry into Material Definitive Agreement) and 2.03 (Creation of Direct Financial Obligation).
• · The material agreement is referenced as Exhibit 10.1 but no details of the agreement are provided in the filing text.

08-06-2026

SI-BONE, Inc. entered into a Third Amendment to Lease on June 5, 2026, extending its lease for office space at 471 El Camino Real, Santa Clara, California by one month to August 31, 2026, with an option to further extend to September 30, 2026. The amendment keeps the premises on an 'AS-IS' basis with no landlord improvement obligations and sets monthly base rent at $43,696 ($2.00 per rentable square foot). The short-term extension suggests the company is managing its real estate footprint conservatively, likely in line with ongoing operational needs.

• · Lease term originally scheduled to expire July 31, 2026; extended to August 31, 2026 with option to extend to September 30, 2026.
• · Tenant must deliver written extension notice by August 15, 2026 to exercise the additional one-month extension.
• · No further extension rights beyond September 30, 2026.
• · Tenant represents it is not a 'qualified commercial tenant' under California law.
• · No default exists under the lease as of the amendment date.

08-06-2026

Celcuity Inc. announced a proposed underwritten public offering of $400 million aggregate principal amount of convertible senior notes due 2032, with an option for underwriters to purchase an additional $60 million. The company intends to use net proceeds to repay outstanding obligations under its loan agreement with Oxford Finance LLC and for working capital and general corporate purposes. The offering is subject to market conditions, and there is no assurance of completion.

• · The convertible notes will mature on August 1, 2032, unless earlier converted, redeemed or repurchased.
• · Interest will be payable semi-annually in arrears.
• · Upon conversion, the company may pay cash, shares of common stock, or a combination.
• · The interest rate, conversion rate, offering price and other terms are to be determined upon pricing.
• · The company has filed a registration statement and preliminary prospectus supplement with the SEC.
• · Joint book-running managers: Jefferies, J.P. Morgan, TD Cowen, Guggenheim Securities.
• · Lead manager: LifeSci Capital; Co-managers: Craig-Hallum and Wolfe | Nomura Alliance.
• · The company's lead therapeutic candidate is gedatolisib, a kinase inhibitor of the PI3K/AKT/mTOR pathway.
• · Phase 3 trial VIKTORIA-1 evaluated gedatolisib in HR+/HER2- advanced breast cancer with PIK3CA WT and MT tumors.
• · Phase 3 trial VIKTORIA-2 is ongoing for first-line treatment of HR+/HER2- advanced breast cancer.
• · Phase 1b/2 trial CELC-G-201 is evaluating gedatolisib with darolutamide in metastatic castration-resistant prostate cancer.

08-06-2026

Mitesco, Inc. (MITI) announced the launch of its RoboAgent Test Bed Team, an initiative to gather feedback from real estate industry leaders as it develops its AI-powered productivity platform. The team includes executives from eXp Realty, Kim Hughes & Company, and The Lotierzo Group. However, the filing provides no financial data, revenue figures, or commercialization timelines, and the company remains in a development-stage phase with ongoing execution risks.

• · Mitesco trades on the OTCQB under ticker MITI.
• · The RoboAgent platform aims to integrate CRM, MLS, and transaction data into prioritized daily actions using AI.
• · The Test Bed Team will evaluate product functionality, workflows, coaching content, integrations, and user experience.
• · Brian Valania emphasized that RoboAgent is 'not about replacing agents—it’s about empowering them.'
• · The company expects Test Bed Team feedback to help refine RoboAgent ahead of broader commercialization.
• · Mitesco operates via two divisions: Centcore (data center cloud services) and Vero Technology Ventures (venture arm for productivity-driven cloud technologies).

08-06-2026

Verano Holdings Corp. filed an 8-K on June 8, 2026, reporting amendments to its charter/bylaws (Items 3.03 and 5.03). The filing does not contain any financial results or operational metrics, so no period-over-period comparisons are available. The amendments are a routine corporate governance matter with no disclosed financial impact.

• · The filing includes Items 3.03 (Material Modification to Rights of Security Holders) and 5.03 (Amendments to Articles of Incorporation or Bylaws).
• · The company's business address is 224 W Hill Street, Suite 400, Chicago, IL 60610.
• · Verano Holdings Corp. is incorporated in Nevada (State of Inc.: NV) with a fiscal year ending December 31.

08-06-2026

Plexus Corp. entered into a Second Amended and Restated Credit Agreement dated June 5, 2026, amending and restating its existing credit facility with JPMorgan Chase Bank, N.A. as Administrative Agent, and including PNC Bank, U.S. Bank, Bank of America, and HSBC as co-agents and joint lead arrangers. The agreement extends the maturity date of the revolving credit facility, re-evidences outstanding obligations, and sets forth terms for loans and other financial accommodations. No specific financial amounts or changes in commitment size are disclosed in the filing.

• · The agreement amends and restates the prior Amended and Restated Credit Agreement dated June 9, 2022.
• · The agreement includes provisions for swing line loans, facility letters of credit, and an increase option for commitments.
• · Financial covenants are outlined in Section 6.18, including an Adjusted Covenant Period mechanism.
• · The agreement covers multiple currencies (Dollars, Euros, Pounds Sterling) with benchmark rates including Adjusted Term SOFR Rate, Adjusted EURIBOR Rate, and Adjusted Daily Simple RFR.
• · The agreement includes a cross-guarantee structure among the company and subsidiary borrowers.

08-06-2026

ATI Inc. completed a $450M offering of 5.875% Senior Notes due 2033 via an underwriting agreement with Goldman Sachs & Co. LLC. The notes mature June 15, 2033, with semiannual interest payments starting December 15, 2026, and include call provisions (make-whole premium before June 2029, par-plus thereafter) and an equity clawback feature allowing redemption of up to 35% at 105.875% using equity offering proceeds. No prior-period or operational financial data is included in this 8-K, so no period-over-period comparisons are available.

• · The Notes were issued under a shelf registration statement and governed by the base Indenture from Sept 2021, as supplemented by the Third Supplemental Indenture dated June 8, 2026.
• · Interest on the Notes is payable semi-annually on June 15 and December 15, commencing December 15, 2026.
• · Before June 15, 2029, ATI may redeem the Notes at a make-whole premium (100% of principal plus applicable premium); on or after June 15, 2029, at specified redemption prices set in the Supplemental Indenture, plus accrued interest.
• · An equity clawback feature permits ATI to redeem up to 35% of the Notes at 105.875% of principal using net proceeds from qualified equity offerings, provided at least 65% of the original principal remains outstanding after each such redemption.
• · The Underwriting Agreement was executed on June 3, 2026, with Goldman Sachs & Co. LLC as representative of the underwriters.
• · ATI has agreed to indemnify the underwriters against certain liabilities, including Securities Act liabilities.

08-06-2026

Hubbell Incorporated priced a $1.9 billion senior notes offering on June 2, 2026, consisting of three tranches: $500 million of 4.650% notes due 2031, $700 million of 4.900% notes due 2033, and $700 million of 5.150% notes due 2036. The net proceeds, together with cash on hand and/or additional borrowings, will be used to finance the proposed acquisition of NSI Electrical Buyer, Inc., repay certain NSI indebtedness, and pay related transaction costs. The offering is expected to close on June 8, 2026, and the company reported 2025 revenues of $5.8 billion.

• · The offering is being made under an effective shelf registration statement on Form S-3.
• · Joint book-running managers are J.P. Morgan Securities LLC, BofA Securities, Inc., and HSBC Securities (USA) Inc.
• · The company's corporate headquarters is located in Shelton, CT.
• · The filing includes extensive forward-looking statements and risk factors related to trade tariffs, inflation, supply chain disruptions, and the proposed acquisition.

08-06-2026

On June 5, 2026, Cerus Corporation entered into two new credit facilities with MidCap Financial: a secured term loan facility of up to $65.0 million (with $35.0 million drawn at closing to refinance existing debt) and a secured revolving credit facility of up to $30.0 million (with $29.9 million drawn at closing). The agreements amend and restate Cerus's existing credit agreements from March 2023, extending the revolving line maturity to June 1, 2031. The new facilities significantly increase Cerus's debt load and include floating-rate interest (SOFR + 5.50% on the term loan, SOFR + 3.70% on the revolver) and a financial covenant requiring trailing twelve-month minimum net revenue, which could strain the company if revenue declines.

• · Cerus repaid $30.0 million of existing term loans on the closing date but drew $35.0 million in new term loan proceeds, increasing net term debt by $5.0 million.
• · The revolving credit facility matures June 1, 2031; interest is paid monthly; loans can be borrowed, repaid, and re-borrowed.
• · An Additional Tranche of up to $30.0 million under the term loan facility is available in increments of $5.0 million, subject to lender approval.
• · The company must pay an exit fee (percentage of amount borrowed) upon final payment of the term loan, and a pro rata portion on any prepayment.
• · Revolving facility includes an unused line fee based on average daily unused allowable borrowing base, a collateral management fee, and a minimum drawn balance requirement.
• · Covenant requires trailing twelve-month minimum net revenue, tested quarterly.
• · Prepayment of term loans is not subject to an early termination fee after the first year from closing (June 5, 2027).
• · Termination fee on revolving facility also waived after the first year from closing.
• · All obligations are secured by substantially all assets (with exclusions).
• · Cross-default provisions include certain material contracts and indebtedness; a material adverse change clause is an event of default.
• · The new term loan borrows $35.0M vs. $30.0M repaid, indicating the company increased total drawn term debt by $5.0M at closing.

08-06-2026

Liftoff Mobile, Inc. filed an 8-K announcing the adoption of an Amended and Restated Certificate of Incorporation, effective upon filing. The amendment reclassifies each share of Class A and Class B common stock into 1.3 shares of a single class of Common Stock, eliminates fractional shares via cash payments, and authorizes 7 billion shares of Common Stock and 700 million shares of Preferred Stock. The filing also establishes board composition and vacancy-filling rights tied to Blackstone's designation rights, but no financial results or operational metrics are disclosed.

• · The reclassification converts each share of Class A and Class B common stock into 1.3 shares of Common Stock, with fractional shares settled in cash.
• · The Board is authorized to issue Preferred Stock in series with varying rights without stockholder approval.
• · Board vacancies and newly created directorships are filled by a majority of remaining directors, except when Blackstone has designation rights, in which case the Designating Stockholder fills vacancies.
• · Directors may be removed with or without cause by a majority vote of outstanding shares when Blackstone has designation rights.

08-06-2026

DaVita Inc. entered into a Ninth Amendment to its Credit Agreement, establishing $500M in new incremental Tranche B-2 Term Loans (2026 Incremental Tranche B-2 Term Loans). The amendment modifies the existing 2019 credit facility, with the loans constituting a single class with prior Tranche B-2 Term Loans. This increases DaVita’s total debt capacity, but there are no specific metrics showing declining performance or flat growth mentioned.

• · The amendment modifies the Credit Agreement dated August 12, 2019.
• · Initial Interest Period for the new loans begins on the Ninth Amendment Effective Date (June 8, 2026) and ends on June 30, 2026.
• · Conditions for effectiveness include receipt of legal opinions, solvency certificate, secretary’s certificate, and borrower representations and warranties being true.

08-06-2026

FS KKR Capital Corp. (NYSE: FSK) completed a public offering of $900 million in 7.500% unsecured notes due 2031, with net proceeds intended for general corporate purposes, including potentially repaying outstanding debt. The offering was led by joint book-running managers including BofA Securities, J.P. Morgan, and KKR Capital Markets, among others. FSK, a leading BDC focused on middle-market U.S. companies, is advised by FS/KKR Advisor, a partnership between Future Standard (over $94 billion AUM) and KKR.

• · BofA Securities, BMO Capital Markets, J.P. Morgan, KKR Capital Markets, RBC Capital Markets and SMBC Nikko acted as joint book-running managers.
• · HSBC, ING, Mizuho, MUFG, TD Securities, Truist, Barclays, BNP Paribas, CIBC, Citigroup, Goldman Sachs, Morgan Stanley, SG Americas, UBS and Standard Chartered acted as joint lead managers.
• · ICBC Standard Bank, Keefe Bruyette & Woods, Lucid Capital Markets, R. Seelaus & Co., and U.S. Bancorp Investments acted as co-managers.
• · Filing type is 8-K with items 1.01 (entry into material definitive agreement), 2.03 (creation of direct financial obligation), 7.01 (regulation FD disclosure) and 9.01 (financial statements and exhibits).
• · Future Standard's AUM of $94 billion is estimated as of March 31, 2026 and includes investments, uncalled commitments, CLOs, JV assets and other managed assets.

08-06-2026

InterPrivate Investment Partners V, Inc. announced the pricing of its $175 million initial public offering of 17,500,000 units at $10.00 per unit. The units will trade on Nasdaq under 'IPVVU' starting June 4, 2026, with the offering expected to close on June 5, 2026. The company is a blank check SPAC targeting a business combination, led by Ahmed M. Fattouh.

• · The units are expected to trade on Nasdaq under ticker 'IPVVU' starting June 4, 2026.
• · Each whole warrant entitles holder to purchase one Class A ordinary share at $11.50 per share.
• · The Company has granted underwriters a 45-day option to purchase up to 2,625,000 additional units to cover over-allotments.
• · The registration statement became effective on June 3, 2026.
• · The Company is an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012.

08-06-2026

Great Elm Capital Corp. amended its Loan, Guarantee and Security Agreement with City National Bank on June 8, 2026, to extend the maturity date of the Revolving Facility to the earlier of June 8, 2029 or March 31, 2029 (if the company's 8.50% notes due 2029 are not refinanced by then). This is a strategic debt management move that adds financial flexibility. The filing discloses no financial performance metrics, so no period-over-period comparisons can be made.

• · The amendment updates the maturity date for borrowings under the Revolving Facility to the earlier of June 8, 2029 and March 31, 2029, conditional on refinancing of the 8.50% notes due 2029.
• · The Loan, Guarantee and Security Agreement was originally dated May 5, 2021.
• · The filing includes a Sixth Amendment to that agreement, filed as Exhibit 10.1.

08-06-2026

Triller Group Inc. amended its Bylaws on June 8, 2026, reducing the stockholder meeting quorum requirement from a majority of voting power to 35% of voting power. This change makes it easier to achieve a quorum but also reduces the threshold needed for stockholder actions, potentially weakening minority shareholder protections.

• · The amendment was approved by the Board of Directors on June 8, 2026.
• · The change applies to Section 2.07 of the Company's Bylaws.
• · The prior quorum requirement was a majority in voting power of shares entitled to vote.
• · The new quorum is 35% in voting power of shares entitled to vote, present in person or by proxy.
• · The filing also includes the full text of the Amended and Restated Bylaws as Exhibit 3.1.

08-06-2026

Vivakor, Inc. announced that its commodities trading platform, Vivakor Supply & Trading, LLC, has entered into a one-year crude oil transaction covering approximately 100,000 barrels per month through the Cushing Terminal, representing an estimated $9 million per month or approximately $108 million annualized revenue based on current market pricing. The agreement runs from June 1, 2026 through May 31, 2027 and reflects the company's strategy of integrating crude oil marketing with its midstream infrastructure platform. No prior period comparisons or negative metrics were provided in the filing.

• · The transaction is a one-year arrangement running from June 1, 2026 through May 31, 2027.
• · The agreement covers approximately 100,000 barrels of crude oil per month through the Cushing Terminal.
• · The estimated $9 million per month is based on current market pricing.
• · The transaction supports Vivakor's integrated infrastructure and supply & trading strategy across logistics, storage, terminaling, transportation, and pipeline-connected operating network.
• · Cushing is described as one of the most important crude oil trading hubs in North America.

08-06-2026

BSTR Holdings (Cayman) and its subsidiary BSTR Newco, LLC amended their existing loan agreement on June 2, 2026, increasing the principal sum by $1.1M from $2.5M to $3.6M. Interest on the additional amount will accrue from the amendment date and be payable annually. The amendment reflects increased borrowing by the company but also adds to its debt obligations.

• · The amendment was executed on June 2, 2026, and filed on June 8, 2026.
• · Interest on the additional $1.1M accrues at the same rate as the original loan but only from the amendment date.
• · First annual interest payment on the additional amount is due on the first anniversary of the original Loan Agreement (March 15, 2027) and will be prorated.
• · The amendment includes waivers of notice, presentment, demand, and jury trial rights by the payor.

08-06-2026

Construction Partners, Inc. amended its credit agreement on June 3, 2026, increasing its revolving credit facility from $500.0 million to $700.0 million. The amendment also adjusts financial covenants, including a minimum interest coverage ratio of 2.75-to-1.00 and a step-down maximum net leverage ratio from 4.75-to-1.00 to 4.00-to-1.00 over future quarters. While the increased liquidity and covenant flexibility are positive, the leverage ratio requirements tighten over time, reflecting a balanced approach to managing debt.

• · The amendment permits designation of certain subsidiaries as 'Immaterial Subsidiaries' not required to be guarantors.
• · The amendment extends the reinvestment period for asset disposition proceeds from 180 days to one year.
• · The amendment introduces 'Limited Condition Transaction' provisions for acquisition financing.
• · The accordion amount is reset to the greater of $400.0 million and Consolidated Adjusted EBITDA for the prior four fiscal quarters.
• · The amendment permits liquidation or dissolution of Immaterial Subsidiaries under certain conditions.
• · The amendment adds a $325.0 million floor to the existing 50% of Consolidated Adjusted EBITDA limit on Qualifying Cash for net leverage calculation.

08-06-2026

Solidion Technology Inc. (STI) announced a $35 million private placement of common stock priced above market under Nasdaq rules, with proceeds expected to fully fund the company through 2028. The funds will accelerate commercialization of its patented Extreme-Climate Battery Technology targeting the Lunar economy and space applications. The offering is expected to close on June 9, 2026, with Titan Partners acting as sole placement agent.

• · The offering is a private placement of common stock priced above market under Nasdaq rules.
• · Proceeds will be used to support commercialization, fulfill customer demand, expand inventory, advance building and testing of prototypes, and for working capital and general corporate purposes.
• · The securities have not been registered under the Securities Act of 1933, and the company will file a resale registration statement with the SEC.
• · Solidion holds over 385 patents covering innovations such as high-capacity, silane-gas-free and graphene-enabled silicon anodes, biomass-based graphite, and advanced lithium-sulfur and lithium-metal technologies.
• · The company has pilot production facilities in Dayton, Ohio, and is headquartered in Dallas, Texas.

08-06-2026

FICO announced a new $2.0 billion stock repurchase authorization, replacing the prior $1.5 billion program, and entered into a $1.5 billion incremental term loan to fund an accelerated share repurchase (ASR) program with Wells Fargo. The ASR program includes an upfront payment of $1.5 billion and an initial delivery of approximately 1,055,100 shares, with final settlement expected by September 30, 2026. This move signals strong capital return to shareholders but increases leverage, as the term loan is fully drawn.

• · The new stock repurchase program is open-ended and replaces the remaining availability under the prior $1.5 billion program.
• · The term loan amendment was entered into on June 5, 2026, and the full $1.5 billion was drawn on the same date.
• · The final number of shares repurchased under the ASR will be based on the volume-weighted average price of FICO's common stock during the term, less a discount and subject to customary adjustments.
• · At final settlement, FICO may receive additional shares or, under certain circumstances, may be required to deliver shares or make a cash payment.
• · The ASR program is expected to be completed by the end of FICO's current fiscal year, September 30, 2026.
• · FICO holds more than 200 U.S. and foreign patents and its FICO Score is used by 90% of top U.S. lenders.

08-06-2026

DevvStream Corp. entered into a Settlement Agreement with Helena Global Investment Opportunities 1 Ltd. to resolve disputes over a $10M convertible note, agreeing to honor $295,000 in conversion notices, credit $2.6M in digital asset collateral, and set remaining debt at $1M. Helena consented irrevocably to DevvStream’s proposed merger with XCF Global and Southern Energy Renewables. The settlement removes a material default uncertainty but leaves $1M debt still convertible at a distressed price.

• · The Settlement Agreement includes a mutual release of all claims related to the transaction documents and disputes, with carve-outs for obligations under the Settlement Agreement and the Remaining Debt.
• · Helena’s consent to the proposed merger and waiver of Section 13 termination rights survive any default by DevvStream under the Settlement Agreement.
• · The settlement resolves previously disclosed disputes that arose after Helena delivered a Notice of Exclusive Control on May 28, 2026.
• · The Remaining Debt remains convertible by Helena at the Event of Default Discount Price per the Note terms.

08-06-2026

American Battery Technology Company (ABAT) announced the reinstatement of a U.S. Department of Energy grant for a $115 million commercial-scale lithium refinery at its Tonopah Flats Lithium Project (TFLP). The grant was initially terminated in October 2025 but reinstated after a successful appeal. The TFLP project has demonstrated a lifetime after-tax NPV@8% of $2.57 billion, an IRR of 21.8%, and a competitive production cost of $4,307 per tonne of lithium hydroxide monohydrate.

• · The grant was reinstated in its entirety with no change to funds awarded or technical/commercial milestones, only an updated schedule.
• · The grant spans five years (initial selection October 2022), with ABTC completing the first two years of contracted milestones.
• · In June 2025, the TFLP was designated a critical mineral Priority Project by the White House's National Energy Dominance Council and FAST-41 Permitting Council.
• · ABTC appealed the termination on October 10, 2025, entered the Informal Dispute Resolution process, and received reinstatement after a final review meeting in December 2025.
• · The Pre-Feasibility Study published in October 2025 supports the project's economic viability.
• · The grant has received support across multiple administrations (Trump, Biden, second Trump).

08-06-2026

Village Farms International, Inc. announced its financial results for the first quarter ended March 31, 2025. Net sales increased 15% to $75.2 million compared to $65.4 million in the same period last year, driven by strong performance in the Canadian cannabis segment. However, the company reported a net loss of $2.1 million, compared to net income of $0.5 million in Q1 2024, reflecting higher operating expenses and a decline in the U.S. produce segment.

• · Canadian cannabis segment net sales increased 25% YoY to $45.0 million.
• · U.S. produce segment net sales decreased 5% YoY to $30.2 million.
• · Gross profit margin improved to 22% from 20% in Q1 2024.
• · Operating expenses increased 18% YoY to $18.5 million.
• · Cash and cash equivalents were $12.3 million as of March 31, 2025.

08-06-2026

CleanCore Solutions, Inc. terminated its Amended and Restated Sales Agreement with Maxim Group LLC and Curvature Securities LLC, effective June 3, 2026. The termination ends the at-the-market offering program, and no further sales will be made under the agreement. Separate waiver and release agreements with each agent remain in effect.

• · The Sales Agreement was originally dated August 29, 2025.
• · The termination is effective as of June 3, 2026.
• · Surviving provisions include those related to indemnification, contribution, and governing law.
• · The agreement is governed by New York law with exclusive jurisdiction in Manhattan courts.

08-06-2026

Alliance Resource Partners, L.P. (ARLP) announced a $206.2 million acquisition of general partner and limited partner interests in AllDale Minerals III & IV, increasing its aggregate economic interest from approximately 5% to 61%. The transaction, expected to close in July 2026, is immediately accretive to free cash flow per unit and will expand ARLP's oil & gas royalty platform to approximately 115,680 net royalty acres, with pro forma leverage expected to remain below 1.0x. However, the acquisition involves related parties of Chairman Joseph W. Craft III, and the implied acquisition multiple of 5.0x projected next-twelve-month Adjusted EBITDA reflects reliance on commodity strip pricing and existing hedges.

• · The transaction was approved by the conflicts committee of the Board of Directors of ARLP's general partner, comprised entirely of independent directors.
• · The acquisition provides entry into the Haynesville shale, a key natural gas resource play supporting LNG export demand.
• · ARLP's acquisition is expected to be funded through cash on hand, borrowings under its revolving credit facility, and a new debt facility at Alliance Minerals, LLC.
• · Pro forma total leverage is expected to remain below 1.0x following closing.
• · The implied acquisition multiple on the interests being acquired by ARLP is approximately 5.0x projected next-twelve-month Adjusted EBITDA, based on commodity strip pricing as of June 5, 2026, and inclusive of existing hedges.
• · The effective date of the agreements is April 1, 2026, with closing expected in July 2026.

08-06-2026

Standard BioTools Inc. (LAB) and Treeline Biosciences have entered into a definitive all-stock merger agreement, with the combined company to operate as Treeline Biosciences (ticker TRLN). The transaction values Standard BioTools at net cash plus $10 million (estimated $460 million), and at closing pre-merger Standard BioTools stockholders will own approximately 16% of the combined company. The combined company is expected to have over $900 million in cash, funding operations into 2029, and will be led by Treeline CEO Josh Bilenker. However, Standard BioTools' legacy Mass Cytometry and Microfluidics businesses will not be operated by Treeline and are being explored for divestiture, with no assurance of any transaction, and Standard BioTools stockholders will receive a CVR for potential proceeds from these legacy assets.

• · Transaction is structured to be tax-free to both Standard BioTools and Treeline shareholders.
• · Standard BioTools stockholders will receive one CVR per share for potential net proceeds from legacy assets (Mass Cytometry, Microfluidics, and up to $50M Illumina earnout).
• · Certain Standard BioTools stockholders have agreed to vote shares in favor of the transaction.
• · Treeline was founded in 2021 and has raised approximately $1.2 billion from life sciences investors.
• · The combined company will trade on Nasdaq under ticker 'TRLN'.
• · Closing expected in second half of 2026, subject to regulatory approvals, Standard BioTools stockholder approval, and other conditions.
• · Treeline's pipeline includes three Phase 1 programs with interim data readouts expected starting in 2027.
• · Standard BioTools is exploring divestiture of its Mass Cytometry and Microfluidics businesses, but there is no assurance any transaction will occur.

08-06-2026

Vivos Therapeutics announced a binding agreement with Streeterville Capital to exchange up to $4.5 million of senior debt into perpetual nonconvertible preferred stock and common stock. The exchange is contingent on completing one or more equity financings and is intended to improve stockholders' equity to comply with Nasdaq listing standards. However, there is no assurance that the financing or exchange will be completed, and the company faces risks including potential delisting.

• · The agreement includes a 90-day suspension of debt repayment calls and a 60-day suspension of securities sales by Streeterville.
• · The exchange is contingent on one or more qualifying equity financings on terms acceptable to the company.
• · In June 2025, Vivos acquired the operating assets of The Sleep Center of Nevada, the largest operator of medical sleep centers in Nevada.
• · The company's devices are FDA cleared for severe OSA in adults and moderate-to-severe OSA in children ages 6-17.
• · OSA affects over 1 billion people worldwide, with 80% or more undiagnosed.

08-06-2026

Ocean Power Technologies (OPTT) announced a $10.0 million registered direct offering of 25,000,000 shares and warrants at $0.40 per unit, priced at a premium to market. The offering, expected to close June 8, 2026, will provide working capital and general corporate purposes. However, the significant dilution from 25 million new shares may pressure existing shareholders, and the company's reliance on such financing highlights ongoing cash needs.

• · The offering was priced at a premium to the prior day's closing price.
• · Common warrants are exercisable six months after issuance at $0.40 per share and expire 6 years from the initial exercise date.
• · Ladenburg Thalmann & Co. Inc. is the exclusive placement agent.
• · The offering is being made under a shelf registration statement on Form S-3 (File No. 333-275843).

08-06-2026

Digimarc Corporation announced the appointment of Paul Carreiro as CEO, effective July 6, 2026, succeeding Riley McCormack who will remain on the Board. Carreiro brings a proven track record of scaling enterprise software platforms, including driving Kinaxis revenue from $90M to over $450M in six years. The company also disclosed an equity offering program to accelerate commercialization and innovation investment, while maintaining a disciplined capital allocation approach.

• · Carreiro propelled Elemica into the elite 'Rule of 50' category over two years.
• · Digimarc is positioning to capture market opportunity from AI-driven workflows in authentication, provenance, and verification.
• · The company has entered into an equity offering program to support commercialization and innovation investment.

08-06-2026

Porsche Innovative Lease Owner Trust 2026-1 filed an 8-K on June 8, 2026, reporting the entry into a material underwriting agreement on June 4, 2026, for the issuance of five classes of asset-backed notes (Class A-1 through A-4) with an aggregate principal balance of $911,000,000. The notes are backed by a pool of retail vehicle leases and related assets, and are expected to close on June 12, 2026. The filing also details a series of related transaction documents, including trust agreements, sale agreements, and servicing agreements, but provides no period-over-period performance data or financial trends.

• · The Underwriting Agreement was entered into on June 4, 2026, with BofA Securities, Inc. acting as representative of the several underwriters.
• · The Notes are registered under a Registration Statement on Form SF-3 (Commission File Nos. 333-290988 and 333-290988-01).
• · The Closing Date for the Notes is anticipated to be June 12, 2026.
• · The underlying assets are retail vehicle leases (Leases) and related Porsche vehicles (Leased Vehicles) allocated to a Transaction SUBI.
• · The filing includes certifications required by Paragraph I.B.1(a) of Form SF-3, attached as Exhibit 36.1.
• · No period-over-period financial comparisons or performance metrics are provided in this filing.

08-06-2026

eXoZymes Inc. announced the pricing of its public offering of 592,270 shares of common stock and 296,135 warrants at $18.00 per unit, expecting gross proceeds of $5.33 million. The offering is set to close on June 9, 2026, with net proceeds intended for development of NCT opportunities and general corporate purposes.

• · Warrants have a redemption right for the Company at $0.01 per share if the stock trades at $17.98 or higher for 20 of 30 trading days.
• · The exercise price of warrants may reset to $0.001 per share if within 12 months the Company sells additional shares at a price below $8.99 per share, provided the original purchaser holds all common stock purchased in this offering.
• · The warrants are not listed on any national trading market or other trading medium.
• · The offering is a dilutive event for existing shareholders, increasing the share count by 592,270 shares and adding potential dilution from warrants exercisable at $11.24.

08-06-2026

Acushnet Holdings Corp. entered into a stock repurchase agreement with Magnus Holdings Co., Ltd. on June 8, 2026, to buy back up to $52.5 million of its common stock on a share-for-share basis as part of its existing $1.25 billion share repurchase authorization. The repurchase will occur through open market or privately negotiated transactions, with pricing based on average purchase prices over specified periods, and the program is set to conclude by September 30, 2026, unless completed earlier.

• · The repurchase agreement is part of Acushnet's existing $1.25 billion share repurchase authorization.
• · The price payable to Magnus will be the average price of shares purchased in the open market or privately negotiated transactions over specified pricing periods.
• · The first pricing period begins June 10, 2026.
• · The determination date for the repurchase is the date when $52.5 million in shares are purchased, any mutually agreed date, or September 30, 2026, whichever occurs first.
• · Obligations are conditioned on no material adverse effect on the Company's business or financial condition since the agreement date.
• · Magnus Holdings Co., Ltd. is a related party; further details are in the Definitive Proxy Statement filed April 17, 2026.

08-06-2026

Newton Golf Company, Inc. (NWTG) entered into a Securities Purchase Agreement to issue convertible promissory notes and warrants for up to $3.0 million in aggregate principal amount. The offering is conducted in reliance on exemptions from registration under the Securities Act, with purchasers representing accredited investor status. The company has authorized the reservation of shares for conversion and exercise of the securities, but the filing does not disclose any specific financial results or performance metrics.

• · The Notes are convertible into shares of Common Stock at par value $0.01 per share.
• · The Warrants are exercisable for shares of Common Stock, with the number of shares set forth on the Schedule of Purchasers.
• · The Company's Board of Directors has approved the Loan Documents based on a reasonable belief that the Loan Amount is appropriate.
• · Purchasers represent that they are accredited investors as defined in Rule 501 under the Securities Act.
• · The Company has reserved the Note Shares and Warrant Shares for issuance upon conversion and exercise.
• · The filing does not include any financial statements, revenue figures, or performance metrics for any period.